PDCD1 and central nervous system cancer: The results implied the significant clinical response and therapeutic advantages to anti-PD-1 immunotherapy (high IPS) in glioma patients with high PSscore compared to those with low PSscore (Fig. 6d–g), but the response to anti-CTLA-4 immunotherapy without significant differences between these two groups.